New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer
- PMID: 18461292
- DOI: 10.1007/s00296-008-0589-5
New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer
Abstract
It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.
Similar articles
-
A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.J Rheumatol. 1987 Feb;14(1):97-101. J Rheumatol. 1987. PMID: 3553591 Clinical Trial.
-
Effects of liposomal prostaglandin E1 on periprocedural myocardial injury in patients with unstable angina undergoing an elective percutaneous coronary intervention.Coron Artery Dis. 2015 Dec;26(8):671-7. doi: 10.1097/MCA.0000000000000294. Coron Artery Dis. 2015. PMID: 26267747 Clinical Trial.
-
Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes.J Rheumatol. 1990 Nov;17(11):1513-4. J Rheumatol. 1990. PMID: 2273493
-
[Treatment of the peripheral vascular diseases with prostaglandin].Nihon Rinsho. 1994 Aug;52(8):2182-6. Nihon Rinsho. 1994. PMID: 7933609 Review. Japanese.
-
[Development of new drugs for intractable vasculitis--lipo-PGE1 and monoclonal antibody].Nihon Rinsho. 1994 Aug;52(8):2187-91. Nihon Rinsho. 1994. PMID: 7933610 Review. Japanese.
Cited by
-
Influence of various treatments including povidone-iodine and healing stimulatory reagents in a rabbit ear wound model.Int Wound J. 2013 Oct;10(5):542-8. doi: 10.1111/j.1742-481X.2012.01016.x. Epub 2012 Jul 9. Int Wound J. 2013. PMID: 22776519 Free PMC article.
-
Study of molecular mechanism of Prostaglandin E1 in inhibiting coronary heart disease.Mol Biol Rep. 2013 Dec;40(12):6701-8. doi: 10.1007/s11033-013-2785-y. Epub 2013 Oct 22. Mol Biol Rep. 2013. PMID: 24146100
-
PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2.PLoS One. 2012;7(3):e33329. doi: 10.1371/journal.pone.0033329. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442685 Free PMC article. Clinical Trial.
-
Effect of Prostaglandin E1 Analog Misoprostol in An Ovalbumin-Induced Allergic Rhinitis Model.Eurasian J Med. 2019 Feb;51(1):75-79. doi: 10.5152/eurasianjmed.2019.19025. Eurasian J Med. 2019. PMID: 30911262 Free PMC article.
-
Therapeutic effect of liposomal prostaglandin E1 in acute lower limb ischemia as an adjuvant to hybrid procedures.Exp Ther Med. 2013 Jun;5(6):1760-1764. doi: 10.3892/etm.2013.1061. Epub 2013 Apr 10. Exp Ther Med. 2013. PMID: 23837069 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous